In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin. BioNTech forecast revenue between 1.7 billion euros and 2.2 billion ...

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 ...

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor ...

BioNTech has slipped into the red in the development of cancer drugs. The company, which is known for its coronavirus vaccine, now wants to cut jobs.

German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...

Stock futures and bond yields fell early on Monday after President Trump did not rule out the possibility that his policies would cause a recession and data showed deflationary pressures building in ...

Freshfields has won a Düsseldorf regional court patent dispute on behalf of client Moderna against German COVID-19 vaccine ...

Wall Street expects BioNTech SE BNTX to report quarterly earnings at 58 cents per share on revenue of $1.15 billion before ...

Republicans have proposed legislation in several states to ban the pioneering technology used in covid shots. Many doctors ...